Abstract
Prostate cancer (PCa) is the most commonly occurring cancer in American men, next to skin cancer. Existing treatment options and surgical intervention are unable to effectively manage this cancer. Therefore, continuing efforts are ongoing to establish novel mechanism-based targets and strategies for its management. The serine/threonine kinases Polo-like kinase (Plk) 1 plays a key role in mitotic entry of proliferating cells and regulates many aspects of mitosis which are necessary for successful cytokinesis. Plk1 is over-expressed in many tumor types with aberrant elevation frequently constituting a prognostic indicator of poor disease outcome. This review discusses the studies which indicate that Plk1 could be an excellent target for the treatment as well as chemoprevention of prostate cancer.
IUBMB Life, 57: 677-682, 2005.
MeSH terms
-
Animals
-
Antibodies / pharmacology
-
Antineoplastic Agents / pharmacology
-
Cell Cycle Proteins / antagonists & inhibitors
-
Cell Cycle Proteins / immunology
-
Cell Cycle Proteins / metabolism*
-
Cell Line, Tumor
-
Cell Transformation, Neoplastic / genetics
-
Chemoprevention
-
Female
-
Glycine / analogs & derivatives
-
Glycine / pharmacology
-
Humans
-
Male
-
Mice
-
Mitosis / drug effects
-
NIH 3T3 Cells
-
Polo-Like Kinase 1
-
Prostatic Neoplasms / drug therapy
-
Prostatic Neoplasms / enzymology*
-
Prostatic Neoplasms / prevention & control
-
Protein Kinase Inhibitors / pharmacology
-
Protein Serine-Threonine Kinases / antagonists & inhibitors
-
Protein Serine-Threonine Kinases / immunology
-
Protein Serine-Threonine Kinases / metabolism*
-
Proto-Oncogene Proteins / antagonists & inhibitors
-
Proto-Oncogene Proteins / immunology
-
Proto-Oncogene Proteins / metabolism*
-
Sulfones / pharmacology
Substances
-
Antibodies
-
Antineoplastic Agents
-
Cell Cycle Proteins
-
Protein Kinase Inhibitors
-
Proto-Oncogene Proteins
-
Sulfones
-
ON 01910
-
Protein Serine-Threonine Kinases
-
Glycine